Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Raloxifene: bone and cardiovascular effects.

C M Francucci1, P Romagni, M Boscaro

  • 1Division of Endocrinology, Department of Internal Medicine, University of Ancona, Italy. cm.francucci@ao-umbertoprimo.marche.it

Journal of Endocrinological Investigation
|March 23, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Second-line tests in the differential diagnosis of neoplastic and non-neoplastic hypercortisolism: a systematic review and meta-analysis.

Journal of endocrinological investigation·2023
Same author

Indication to dynamic and invasive testing in Cushing's disease according to different neuroradiological findings.

Journal of endocrinological investigation·2021
Same author

Frequently asked questions and answers (if any) in patients with adrenal incidentaloma.

Journal of endocrinological investigation·2021
Same author

Primary aldosteronism: considerations about the evaluation of the aldosterone to renin ratio during canrenone treatment.

Journal of endocrinological investigation·2021
Same author

COVID-19 infection and glucocorticoids: update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficiency.

Journal of endocrinological investigation·2020
Same author

Towards the tailoring of glucocorticoid replacement in adrenal insufficiency: the Italian Society of Endocrinology Expert Opinion.

Journal of endocrinological investigation·2019
Same journal

Inhibition of TGF-β1/Smad signaling reverses the dedifferentiated phenotype of thyroid cancer cells in three-dimensional culture.

Journal of endocrinological investigation·2026
Same journal

lncRNA PANDAR predicts adverse pregnancy outcomes and reflects hyperglycemia-associated cellular stress in gestational diabetes mellitus.

Journal of endocrinological investigation·2026
Same journal

Correction: Early in, early out: reproductive lifespan timing and cardiometabolic risk in women.

Journal of endocrinological investigation·2026
Same journal

Adult mice are more susceptible to high-fat diet-induced visceral adiposity and insulin resistance than juvenile mice.

Journal of endocrinological investigation·2026
Same journal

Lactobacillus gasseri alleviates type 2 diabetes via modulation of gut microbiota-host metabolic networks.

Journal of endocrinological investigation·2026
Same journal

Rare causes of exogenous Cushing's Syndrome: a challenge for endocrinologists.

Journal of endocrinological investigation·2026
See all related articles

Raloxifene (RLX), a selective estrogen receptor modulator (SERM), shows promise for osteoporosis, breast cancer, and cardiovascular disease in post-menopausal women. It offers a favorable safety profile for various women's health conditions.

Area of Science:

  • Pharmacology
  • Endocrinology
  • Oncology

Background:

  • Raloxifene (RLX) is a selective estrogen receptor modulator (SERM) approved for post-menopausal osteoporosis.
  • RLX's potential in reducing breast cancer and cardiovascular disease risk is under investigation.

Purpose of the Study:

  • To evaluate the efficacy and safety of RLX in post-menopausal women.
  • To explore RLX's role beyond osteoporosis treatment.

Main Methods:

  • Review of existing clinical data and studies on RLX.
  • Analysis of RLX's mechanism of action as a SERM.

Main Results:

  • RLX acts as an estrogen agonist in bone and lipid metabolism, but an antagonist in breast and uterine tissues.

Related Experiment Videos

  • Preliminary data suggest a favorable risk-benefit profile for RLX.

    • Conclusions:

    • RLX is a promising agent for preventing and treating post-menopausal osteoporosis.
    • RLX demonstrates potential for managing other disorders in post-menopausal women, including breast cancer and cardiovascular disease.